Retatrutide cost and availability

Retatrutide is not yet FDA-approved or commercially available as a pharmaceutical product. It exists in two markets: the clinical trial pipeline (where Eli Lilly is conducting Phase 3 TRIUMPH trials) and the research peptide market (where it is sold for research purposes only). This page covers current pricing in both contexts, the expected timeline for FDA approval, and what the pharmaceutical cost might look like post-approval.

Retatrutide cost: current research pricing

Research-grade retatrutide is available through peptide suppliers at prices ranging from approximately $150–400 per 5 mg vial and $250–700 per 10 mg vial, depending on the supplier, purity level, and quantity ordered. At the clinical trial dose of 12 mg per week, a single 10 mg vial provides less than one week of treatment — making the research-grade cost approximately $250–700 per week, or $1,000–2,800 per month.

This is significantly more expensive than research-grade semaglutide or tirzepatide, reflecting retatrutide's newer status and more complex synthesis as a triple-agonist peptide. As more suppliers enter the market and manufacturing scales, research-grade prices are expected to decrease — but they will remain substantially higher than pharmaceutical pricing once the drug is approved.

Retatrutide cost: expected pharmaceutical pricing

Post-FDA approval, retatrutide is expected to be priced competitively with Eli Lilly's existing obesity drug Zepbound (tirzepatide), which launched at approximately $1,060 per month ($12,720 per year) at list price. Given that retatrutide represents an advancement over tirzepatide — with potentially greater weight loss efficacy — Eli Lilly may price it at a premium, potentially $1,200–1,500 per month at list price. However, competitive dynamics in the increasingly crowded obesity drug market may moderate pricing. The actual cost to patients will depend heavily on insurance coverage, manufacturer copay programs, and pharmacy benefit manager negotiations — the same factors that currently determine the out-of-pocket cost of Wegovy and Zepbound.

Retatrutide availability: FDA approval timeline

Retatrutide is currently in Phase 3 clinical trials under the TRIUMPH program. The expected regulatory timeline is Phase 3 trial completion (TRIUMPH-1 primary endpoint) in late 2025 to mid-2026, NDA submission to the FDA in 2026 (assuming positive Phase 3 data), FDA review period of 6–12 months (standard review) or potentially faster under priority review, and potential FDA approval in late 2026 to 2028. This timeline is an estimate based on typical drug development timelines and publicly available information from Eli Lilly. Delays in Phase 3 enrollment, unexpected safety signals, or FDA requests for additional data could push approval later. Conversely, breakthrough therapy designation or priority review could accelerate the timeline.

Retatrutide availability: insurance coverage outlook

Insurance coverage for obesity drugs has been the primary barrier to patient access for semaglutide (Wegovy) and tirzepatide (Zepbound). Many insurers and pharmacy benefit managers have restricted or excluded coverage for anti-obesity medications, citing high costs. The landscape is evolving — Medicare coverage for obesity drugs has been debated in Congress, and some private insurers have expanded coverage as clinical evidence for cardiovascular and metabolic benefits has accumulated.

Retatrutide's coverage prospects will depend on several factors: whether Phase 3 data confirms cardiovascular benefit (which has been the strongest driver of insurance coverage for semaglutide), Eli Lilly's pricing strategy (competitive pricing improves coverage decisions), the overall obesity drug market trajectory (if coverage expands for the class generally, retatrutide benefits), and whether retatrutide receives any FDA designations (breakthrough, priority review) that signal clinical urgency.

Retatrutide availability: current access options

There are currently three ways to access retatrutide. Clinical trial enrollment through Eli Lilly's TRIUMPH program provides pharmaceutical-grade retatrutide at no cost to qualifying participants (check clinicaltrials.gov for active enrollment sites). Research peptide suppliers offer research-grade retatrutide for purchase at the prices described above, labeled for research use only. Compounding pharmacies in some jurisdictions may compound retatrutide if prescribed off-label by a physician, though this is uncommon given the compound's investigational status and the lack of established compounding protocols.